EML1

Across TCGA pan-cancer cohorts, EML1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EML1 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher EML1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EML1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and SKCM show a favorable association.

PAAD, SARC, and UCEC are the cancer types where EML1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.028	0.614	<.001	24	view →
SARC	DFS	Median	All	0.094	0.611	.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	All	0.469	0.663	.035	4	view →
COAD	DFS	Median	III,IV	0.280	0.652	.043	3	view →
LUAD	OS	Median	III,IV	1.000	0.273	.041	2	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EML1–PAAD (OS)

Open the PAAD breakdown →